Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma

作者：Y. Wang, R. Rosell, Fred R. Hirsch, Shun Lu, Ramaswamy Govindan, K. Park, Solange Peters, J.J. Zhang · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.11.008 · 被引用次数：8 · 研究领域：Cancer Immunotherapy and Biomarkers、Immunotherapy and Immune Responses、Lung Cancer Treatments and Mutations

Advanced-stage lung squamous-cell carcinoma (LUSC) remains a therapeutic challenge. Although immune checkpoint inhibitors (ICIs) have revolutionized LUSC treatment, only a small subset of LUSC patients can achieve durable clinical benefits, underscoring the need for novel strategies. Emerging immunotherapy strategies have demonstrated early evidence of promise for LUSC patients, particularly multi-specific antibodies and fusion proteins, antibody-drug conjugates, adoptive cell therapies, and cancer vaccines. Additionally, advances in multi-omics and artificial intelligence offer potential for precise immunotherapy by deciphering the complex tumor-immune microenvironment and predicting therapeutic responses. The future of LUSC treatment lies in rational multi-target and biological therapies to boost immune cytotoxicity, as well as innovative technologies to refine patient selection. This review highlights the evolving landscape and outlines a roadmap for next-generation immunotherapies in LUSC.